{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:41Z","timestamp":1792218641030,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R\/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older. GO is a CD33-directed antibody drug conjugate linked to the cytotoxic antibiotic calicheamicin. It originally received accelerated approval for treatment of older patients with relapsed CD33-positive AML in 2000, but it was withdrawn from the market in 2010 when the confirmatory trial failed to demonstrate clinical benefit among safety concerns, such as a higher rate of induction fatalities on the GO combination arm compared with chemotherapy alone. In addition, GO was associated with hepatic veno-occlusive disease (VOD), which has substantial morbidity and mortality. Pharmacokinetic analyses suggested a lower maximum concentration of GO would result in less VOD without affecting target saturation or efficacy. A meta-analysis across dose schedules of GO in patients with R\/R AML showed that a lower-dose \u201cfractionated\u201d schedule of 3 mg\/m2 days 1, 4, and 7 was associated with less early mortality, hemorrhage, and VOD, without an apparent decrease in complete remission (CR) rate. MyloFrance 1 was a single-arm study evaluating response rates in patients with relapsed CD33-positive AML treated with the lower-dose fractionated GO regimen. The CR rate was 26% (95% confidence interval 16%\u201340%). Common adverse reactions were fever, infections, nausea, vomiting, constipation, bleeding, increased liver enzymes, and mucositis. There were no cases of VOD. These results supported the approval of GO as monotherapy for R\/R CD33-positive AML using the lower-dose fractionated regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Gemtuzumab ozogamicin (GO) 3 mg\/m2 days 1, 4, and 7 is an active regimen for induction of remission when used to treat patients with relapsed or refractory CD33-positive acute myeloid leukemia without curative intent. The risks of hepatic veno-occlusive disease and early mortality with this regimen appear to be lower than reported previously for GO 9 mg\/m2 days 1 and 15. The data were not sufficient to enable conclusions about the safety of GO in children younger than 2 years of age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0604","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T14:36:47Z","timestamp":1523543807000},"page":"1103-1108","source":"Crossref","is-referenced-by-count":262,"title":["FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia"],"prefix":"10.1093","volume":"23","author":[{"given":"Kelly J.","family":"Norsworthy","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Ko","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy S.","family":"John","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann T.","family":"Farrell","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"2021122511121967600_onco12444-bib-0001","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0003","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajh.23498","article-title":"Outcome of older patients with acute myeloid leukemia in first relapse","volume":"88","author":"Sarkozy","year":"2013","journal-title":"Am J Hematol"},{"key":"2021122511121967600_onco12444-bib-0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.leukres.2014.11.009","article-title":"Azacitidine for the treatment of relapsed and refractory AML in older patients","volume":"39","author":"Itzykson","year":"2015","journal-title":"Leuk Res"},{"key":"2021122511121967600_onco12444-bib-0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0006","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122511121967600_onco12444-bib-0007"},{"key":"2021122511121967600_onco12444-bib-0008","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"2021122511121967600_onco12444-bib-0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2407-6-172","article-title":"Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed\/refractory myeloid leukemia","volume":"6","author":"Brethon","year":"2006","journal-title":"BMC Cancer"},{"key":"2021122511121967600_onco12444-bib-0011","first-page":"106","article-title":"Gemtuzumab ozogamicin (Mylotarg\u00ae) as single agent treatment for adult patients with acute myeloid leukemia (AML)","author":"Thomas","year":"2005","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0012","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V120.21.4342.4342","article-title":"Standard administration and fractionated administration of gemtuzumab ozogamicin for patients with relapsed and refractory acute myeloid leukemia","volume":"120","author":"Yahagi","year":"2012","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0013","year":"2017"},{"key":"2021122511121967600_onco12444-bib-0014","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12185-013-1275-2","article-title":"Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): A prospective observational study of 482 patients in routine clinical practice","volume":"97","author":"Tallman","year":"2013","journal-title":"Int J Hematol"},{"key":"2021122511121967600_onco12444-bib-0015","first-page":"269","article-title":"Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Reinhardt","year":"2004","journal-title":"Onkologie"},{"key":"2021122511121967600_onco12444-bib-0016","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V116.21.1075.1075","article-title":"Gemtuzumab ozogamicin in refractory childhood acute myeloid leukemia","volume":"116","author":"Reinhardt","year":"2010","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0017","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: First clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0018","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: Results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122511121967600_onco12444-bib-0019","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33 positive AML","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122511121967600_onco12444-bib-0020","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"2021122511121967600_onco12444-bib-0021","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood.V124.21.376.376","article-title":"Final analysis of the ALFA 0701 study","volume":"124","author":"Castaigne","year":"2014","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0022","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"2021122511121967600_onco12444-bib-0023","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: Results from the randomized phase III children's oncology group trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"2021122511121967600_onco12444-bib-0026","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0609.2005.00623.x","article-title":"Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"76","author":"Heiden","year":"2006","journal-title":"Eur J Haematol"},{"key":"2021122511121967600_onco12444-bib-0027","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0028","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122511121967600_onco12444-bib-0029","year":"2017"},{"key":"2021122511121967600_onco12444-bib-0030","year":"2007"},{"key":"2021122511121967600_onco12444-bib-0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.seminoncol.2009.03.007","article-title":"Acute leukemia in adolescents and young adults","volume":"36","author":"Advani","year":"2009","journal-title":"Semin Oncol"},{"key":"2021122511121967600_onco12444-bib-0032","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1078-0432.CCR-15-2646","article-title":"Lessons learned: Dose selection of small molecule-targeted oncology drugs","volume":"22","author":"Bullock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122511121967600_onco12444-bib-0033","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819021000016078","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia","volume":"43","author":"Roboz","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2021122511121967600_onco12444-bib-0034","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","article-title":"Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk Lymphoma"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1103\/41915425\/oncolo_23_9_1103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1103\/41915425\/oncolo_23_9_1103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:12:59Z","timestamp":1640412779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/9\/1103\/6439685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,4,12]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0604","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,4,12]]}}}